Chaperone documentation for clinical notes (provided by Birmingham Children's Hospital):
Information on guidelines
Included in this page are BSPED guidelines (commissioned and developed by BSPED) and BSPED endorsed guidelines (produced by other national bodies). Each patient should be considered as an individual in the context of their condition and other medication and therefore the readers' discretion is required in the application of their use of these guidelines. Every effort has been made to ensure the factual accuracy of the contents but no liability can be accepted for any litigation, claims or complaints arising from the use of the guidelines.
If you have a query or comment, or would like to raise a concern regarding a BSPED guideline, or any guideline on this page, please contact the BSPED Office who will ensure your message is passed to the BSPED Clinical Guidelines Officer and Clinical Committee.
BSPED Guidelines (guidelines produced for the BSPED)
The guidelines included on this page have been commissioned and developed by BSPED and reflect the Society's views on best practice for the majority of patients with that condition.
BSPED Endorsed Guidelines
These guidelines are produced by accredited national bodies (e.g. NICE, RCPCH, ACDC, SIGN), of which BSPED are stakeholders. BSPED may have been involved in the development of these guidelines but are not the original authors of these guidelines. Please review the BSPED Clinical Guideline Endorsement document for the process. Authors of guidelines are required to sign the BSPED Declaration of Interest form (definitions of conflicting interests are listed on the form).
Category | Guideline | Type | Source | Date of document | Review date |
Adrenal Insufficiency | BSPED | BSPED | Nov 2022 | Nov 2025 | |
Bone | Endorsed | DMD Care UK | Aug 2020 | Aug 2023 | |
Bone | Endorsed | DMD Care UK | Aug 2020 | Aug 2023 | |
DSD | Endorsed | Society for Endocrinology | April 2021 | April 2024 | |
Growth | BSPED | BSPED | Apr 2021 | April 2024 | |
Growth |
Shared care guidelines: Paediatric use of Recombinant Human Growth Hormone (r-hGH) |
BSPED | BSPED | Dec 2023 | Jan 2027 |
Growth | BSPED | BSPED | May 2024 | May 2027 | |
Growth |
Recommendations for IGF-1 Therapy in Children with Severe Insulin Resistance Syndromes |
BSPED | BSPED | May 2024 | May 2027 |
Growth | Growth Monitoring for Children with Chronic Kidney Disease | Endorsed | BSPED/BAPN/PRING | March 2024 | March 2027 |
Puberty / Gonads | Hormone Supplementation for Pubertal Induction in Girls | BSPED | BSPED | June 2022 | June 2025 |
Puberty / Gonads | Testosterone Replacement Guidelines | BSPED | BSPED | August 2024 | August 2027 |
Puberty / Gonads | Shared care guidelines: Use of Gonadotrophin Releasing Hormone (GnRH) Agonists | BSPED | BSPED | Apr 2021 | Apr 2025 |
Puberty / Gonads | GnRH Analogue Stimulation Testing to Investigate Precocious Puberty | BSPED | BSPED | Jul 2021 | July 2025 |
Oncology | CCLG: Rare Endocrine Tumour guidelines: Craniopharyngioma | Endorsed | CCLG | 2021 | 2026 |
Oncology | CCLG: Rare Endocrine Tumour guidelines: Idiopathic thickened pituitary stalk (iTPS) and/or idiopathic central diabetes insipidus (CDI) | Endorsed | CCLG | 2021 | 2026 |
Turner Syndrome | Clinical Practice Guidelines for the Care of Girls and Women with Turner Syndrome | Endorsed | ESPE/International Consensus | 2017 | 2021 |
Local/ Other Endocrine Guidelines and Useful Resources
These guidelines are local/other endocrine guidelines which have been made available to BSPED members. The BSPED have not been involved in the development of these guidelines and take no responsibility for the content. Please note local guidelines may vary between Trusts.
If a local trust wishes to publish their guidelines on the BSPED website, please email the BSPED Office ([email protected]) and we will put you in touch with our Clinical Guideline Officer, Dr Jarod Wong.
Category | Guideline | Type | Source | Date of document |
Adrenal |
The Investigation of suspected Paediatric Cushing’s Syndrome |
Supported | Barts and the London School of Medicine | April 2021 |
Growth |
Recombinant IGF-1 Therapy in Children with Severe Primary IGF-1 Deficiency |
Supported | Barts and the London School of Medicine | April 2021 |
Puberty/Gonads | Supported | QMUL/Barts/UCLH/Alder Hey | April 2022 | |
Thyroid | Supported | British Thyroid Association Guideline management of Paediatric Graves disease | 2022 | |
Hyperinsulinism | Supported | UK national consensus | 2023 |
Guideline | Type | Source | Date of document /last updated | Review date |
BSPED | BSPED | Nov 2021 | Nov 2024 | |
BSPED | BSPED | Nov 2021 | Nov 2024 | |
BSPED | BSPED | Nov 2021 | Nov 2024 | |
Diabetes (type 1 and type 2) in children and young people: diagnosis and management |
Endorsed | NICE | Dec 2020 | May 2023 |
ACDC Endorsed Diabetes Guidelines
Please refer to the ACDC website for Endorsed Guidelines for the most up to date diabetes guidelines listed below.
Guideline | Type | Source |
Executive summary - A Practical Approach to the Management of Type 2 Diabetes in children and young people under 18yrs | Endorsed | ACDC/BSPED |
Care of the Well Child-Newly Diagnosed with Type 1 Diabetes | Endorsed | ACDC/BSPED |
Sick day guideline executive summary v4 | Endorsed | ACDC/BSPED |
Sick day guideline Main V4 | Endorsed | ACDC/BSPED |
Management of Hypoglycaemia in Children and Young People with Type 1 Diabetes | Endorsed | ACDC/BSPED |
A Practical Approach to the Self Management of Diabetes As An Inpatient for Children and Young People Under 18 years | Endorsed | ACDC/BSPED |
A Practical Approach to the Management of Continuous Glucose Monitoring (CGM) / Real-Time Flash Glucose Scanning (FGS) in Type 1 Diabetes Mellitus in Children and Young People Under 18 years | Endorsed | ACDC/BSPED |
A Practical Approach to the Management of Steroid, Chemotherapy or Transplant Induced Hyperglycaemia or Diabetes in Children and Young People Under 18 years in the Acute or Inpatient Setting | Endorsed | ACDC/BSPED |
Dexcom G4 CGM Training Leaflet for Healthcare Professionals and Patients | Endorsed | ACDC/BSPED |
Dexcom G5 CGM Training Leaflet for Healthcare Professionals and Patients | Endorsed | ACDC/BSPED |
Dexcom G6 CGM Training Leaflet for Healthcare Professionals and Patients | Endorsed | ACDC/BSPED |
Medtronic 640G Training Leaflet for Healthcare Professionals and Patients | Endorsed | ACDC/BSPED |
Libre FGS Training Leaflet for Healthcare Professionals and Patients | Endorsed | ACDC/BSPED |
Care of children under 18 years with Diabetes Mellitus undergoing Surgery - currently being updated | Endorsed | ACDC/BSPED |
Executive Summary: A Practical Approach to the Management of Continuous Glucose Monitoring (CGM) / Real-Time Flash Glucose Scanning (FGS) in Type 1 Diabetes Mellitus in Children and Young People Under 18 years | Endorsed | ACDC/BSPED |
Practical Management of Hyperglycaemic Hyperosmolar State (HHS) in children | Endorsed | ACDC/BSPED |
Management of Type 1 Diabetes Mellitus during illness in children and young people under 18 years (Sick Day Rules) | Endorsed | ACDC/BSPED |
Executive Summary- Management of Type 1 Diabetes Mellitus during illness in children and young people under 18 years (Sick Day Rules) | Endorsed | ACDC/BSPED |
Patient Advice for Management of Type 1 Diabetes Mellitus during illness in children and young people under 18 years (Sick Day Rules) | Endorsed | ACDC/BSPED |
*BSPED DKA Guidelines: The Clinical Committee of BSPED are aware that NICE has published its revised guidance on the management of Type 1 and Type 2 Diabetes in Children and Young People(CG 18) We are also aware that this revised NICE guidance differs from the current interim BSPED guidance on the cloud the fluid management of DKA. The Clinical Committee plan to review this situation very quickly but do not feel that the current BSPED DKA guidance need to be removed from the website while this review and revision takes place.
Chaperone documentation for clinical notes (provided by Birmingham Children's Hospital):